Condition: Metastatic Renal Cell Carcinoma (mRCC) · Sponsor: Hospital of Macerata
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC. Two Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations
This description comes directly from the study's public registry record.
Matteo Santoni, MD, PhD · +3907332572960 · mattymo@alice.it
Giulia Sorgentoni, PhD · giulia.sorgentoni@libero.it
Always discuss trial participation with your own doctor first.
| Ospedale di Macerata, UOC Oncologia | Province of Macerata, Macerata, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05287464